Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCastro, M.en
dc.contributor.authorRubin, A.en
dc.contributor.authorLaviolette, M.en
dc.contributor.authorFiterman, J.en
dc.contributor.authorLima, M.en
dc.contributor.authorShah, P.en
dc.contributor.authorFiss, E.en
dc.contributor.authorOlivenstein, R.en
dc.contributor.authorThomson, N.en
dc.contributor.authorNiven, R.en
dc.contributor.authorPavord, I.en
dc.contributor.authorSimoff, M.en
dc.contributor.authorDuhamel, D.en
dc.contributor.authorMcEvoy, C.en
dc.contributor.authorBarbers, R.en
dc.contributor.authorten Hacken, N.en
dc.contributor.authorWechsler, M.en
dc.contributor.authorHolmes, M.en
dc.contributor.authorPhillips, M.en
dc.contributor.authorErzurum, S.en
dc.contributor.authoret al.en
dc.identifier.citationAmerican Journal of Respiratory and Critical Care Medicine, 2010; 181(2):116-124en
dc.description.abstractRationale: Bronchial thermoplasty (BT) is a bronchoscopic procedure in which controlled thermal energy is applied to the airway wall to decrease smooth muscle. Objectives: To evaluate the effectiveness and safety of BT versus a sham procedure in subjects with severe asthma who remain symptomatic despite treatment with high-dose inhaled corticosteroids and long-acting β2-agonists. Methods: A total of 288 adult subjects (Intent-to-Treat [ITT]) randomized to BT or sham control underwent three bronchoscopy procedures. Primary outcome was the difference in Asthma Quality of Life Questionnaire (AQLQ) scores from baseline to average of 6, 9, and 12 months (integrated AQLQ). Adverse events and health care use were collected to assess safety. Statistical design and analysis of the primary endpoint was Bayesian. Target posterior probability of superiority (PPS) of BT over sham was 95%, except for the primary endpoint (96.4%). Measurements and Main Results: The improvement from baseline in the integrated AQLQ score was superior in the BT group compared with sham (BT, 1.35 ± 1.10; sham, 1.16 ± 1.23 [PPS, 96.0% ITT and 97.9% per protocol]). Seventy-nine percent of BT and 64% of sham subjects achieved changes in AQLQ of 0.5 or greater (PPS, 99.6%). Six percent more BT subjects were hospitalized in the treatment period (up to 6 wk after BT). In the posttreatment period (6–52 wk after BT), the BT group experienced fewer severe exacerbations, emergency department (ED) visits, and days missed from work/school compared with the sham group (PPS, 95.5, 99.9, and 99.3%, respectively). Conclusions: BT in subjects with severe asthma improves asthma-specific quality of life with a reduction in severe exacerbations and healthcare use in the posttreatment period.en
dc.description.statementofresponsibilityMario Castro…Mark Holmes…for the AIR2 Trial Study Groupen
dc.publisherAmerican Thoracic Societyen
dc.rights© 2010 The American Thoracic Societyen
dc.subjectasthma; Alair Bronchial Thermoplasty System; bronchial thermoplasty; bronchoscopic procedure; Asthma Quality of Lifeen
dc.titleEffectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: A multicenter, randomized, double-blind, sham-controlled clinical trialen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.